New drug cocktail shows promise for Tough-to-Treat lymphomas
NCT ID NCT04479267
First seen Oct 31, 2025 · Last updated Jun 19, 2026 · Updated 41 times
Summary
This phase II trial tests whether adding polatuzumab vedotin to standard chemotherapy improves outcomes for people with aggressive B-cell lymphomas, including double-hit and triple-hit lymphoma. The study enrolled 8 previously untreated patients. The goal is to see if the combination leads to more complete remissions than chemo alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
polatuzumab vedotin
What this could lead to
If successful, this could point toward a more effective first-line treatment for aggressive lymphomas like double-hit lymphoma.
What could go wrong
This is a very small, early-phase trial with only 8 participants, so results may not apply broadly. The drug combination also carries risks of serious side effects from chemotherapy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.